Department of Pharmaceutical & Toxicological Chemistry, Volgograd State Medical University, Paversushikh Bortsov Sq., 1, Volgograd 400131, Russia.
Bioorg Med Chem. 2011 Oct 1;19(19):5794-802. doi: 10.1016/j.bmc.2011.08.025. Epub 2011 Aug 17.
Non-nucleoside reverse transcriptase inhibitors (NNRTI) are key components in highly active antiretroviral therapy for treating HIV-1. Herein we present the synthesis for a series of N1-alkylated uracil derivatives bearing ω-(2-benzyl- and 2-benzoylphenoxy)alkyl substituents as novel NNRTIs. These compounds displayed anti-HIV activity similar to that of nevirapine and several of them exhibited activity against the K103N/Y181C RT mutant HIV-1 strain. Further evaluation revealed that the inhibitors were active against most nevirapine-resistant mono- and di-substituted RTs with the exception of the V106A RT. Thus, the candidate compounds can be regarded as potential lead compounds against the wild-type virus and drug-resistant forms.
非核苷类逆转录酶抑制剂(NNRTI)是治疗 HIV-1 的高效抗逆转录病毒疗法的关键组成部分。本文介绍了一系列带有ω-(2-苄基和 2-苯甲酰氧基)烷基取代基的 N1-烷基尿嘧啶衍生物的合成,作为新型 NNRTIs。这些化合物表现出与奈韦拉平相似的抗 HIV 活性,其中一些化合物对 K103N/Y181C RT 突变 HIV-1 株具有活性。进一步评估表明,这些抑制剂对大多数奈韦拉平耐药的单取代和双取代 RT 具有活性,除了 V106A RT 之外。因此,候选化合物可以被视为针对野生型病毒和耐药形式的潜在先导化合物。